Citryll

Series-B+
citryll.com Biotech & Healthcare Oss, The Netherlands Founded 2015 11-50
Total Funding $113.4M
Latest Round $92.5M Series-B+
Last Announced Dec 9, 2024
Investors 10 Backers
Decision Makers 6 Verified

About Citryll

Citryll is pioneering treatments for immune-mediated inflammatory diseases targeting Neutrophil Extracellular Traps with CIT-013.

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Series-B+
Global Headquarters Oss, The Netherlands
Year Founded 2015
Team Size 11-50
Tracked Since Oct 1, 2026

Web & Domain Identity

Official Website citryll.com
Domain Registered Date Sep 27, 2012

Social & Network Presence

X / Twitter Profile Not linked
LinkedIn Corporate Not linked

Company Milestones & Timeline

4 Events
  1. Capital Raise

    Raised $92,500,000 · Series-B+

    fundraisingfox.com

  2. Capital Raise

    Raised $20,879,100 · Series-B+

  3. Milestone

    Company founded

    Oss, The Netherlands

  4. Milestone

    Website domain registered

    citryll.com

Investors & Backers

10
BioGeneration Ventures
BOM
BrightGene
Curie Capital
Forbion Capital Partners
Johnson & Johnson Innovation
ModiQuest B.V.
Novartis Venture Fund
Pureos Bioventures
Seventure Partners

Funding History

2 Rounds
Series-B+ · Dec 9, 2024
Series-B+ · Jul 2, 2020
$20,879,100 Source

Founders & Leadership

4

Eric Meldrum

Chief Scientific Offcier & Interim CEO

Work email & phone locked Unlock →

Helmuth van Es

Founder

Work email & phone locked Unlock →

Maarten Kraan

Chief Medical Officer

Work email & phone locked Unlock →

Renato Chirivi

co-founder

Work email & phone locked Unlock →

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

START FREE WITH 50 CREDITS
Recently funded startups
New SaaS launches
Never pay twice for contacts